New FDA-approved drug makes severe food allergies less life-threatening
Ars Technica
|
Contributed by: Reid Stephan
Summary
FDA approves Omalizumab (Xolair) to reduce food allergy reactions. Effective in trial subjects with multiple allergies, blocks allergic responses by binding immunoglobulin E. Not universal cure, continued vigilance required. Long-term effectiveness and combination with oral immunotherapy being researched. Side effects include injection reactions, fever, potential pain, infections, malignancies.
